Consensus on biomarkers for neuroendocrine tumour disease. Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J (2015) Lancet Oncol 16: e435-e446 A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ (2015) Sci Transl Med 7: 302ra136 NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ (2004) Cancer Res 64: 5489-95 Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, Abdulkadir SA (2010) Oncogene 29: 2477-87 Early onset pancreatic malignancies: Clinical characteristics and survival associations. Beeghly-Fadiel A, Luu HN, Du L, Shi C, McGavic DP, Parikh AA, Raskin L (2016) Int J Cancer 139: 2169-77 Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC (2016) J Nucl Med 57: 708-14 Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors. Gonzalez RS, Cates JMM, Shi C (2018) Mod Pathol 31: 1560-1566 Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C (2014) Mod Pathol 27: 1288-95 Neuroendocrine tumors. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA, National Comprehensive Cancer Networks (2012) J Natl Compr Canc Netw 10: 724-64 NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC, NCCN Neuroendocrine Tumors Panel Members (2009) J Natl Compr Canc Netw 7: 712-47 Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis. Fata CR, Gonzalez RS, Liu E, Cates JM, Shi C (2017) Am J Surg Pathol 41: 128-133 Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A (2008) Am J Surg Pathol 32: 420-5 Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J (2010) Am J Surg Pathol 34: 300-13 Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Kauffmann RM, Wang L, Phillips S, Idrees K, Merchant NB, Parikh AA (2014) Ann Surg Oncol 21: 3422-8 Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2. Gupta A, Yu X, Case T, Paul M, Shen MM, Kaestner KH, Matusik RJ (2013) Prostate 73: 582-9 Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB (2007) AJR Am J Roentgenol 188: 1201-7 Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors. Salaria S, Means A, Revetta F, Idrees K, Liu E, Shi C (2015) Am J Clin Pathol 144: 642-8 Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? Numbere N, Huber AR, Shi C, Cates JMM, Gonzalez RS (2019) Histopathology 74: 424-429 Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. Gibson WE, Gonzalez RS, Cates JMM, Liu E, Shi C (2018) Hum Pathol 79: 109-115 SOX2 expression in the developing, adult, as well as, diseased prostate. Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ (2014) Prostate Cancer Prostatic Dis 17: 301-9 Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the appendix. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134: 171-5 Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134: 176-80 Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134: 181-6 Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Members of the Cancer Committee, College of American Pathologists (2010) Arch Pathol Lab Med 134: 187-91 Surgical treatment of non-functioning pancreatic islet cell tumors. Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB (2005) J Surg Oncol 89: 170-85 Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Schmidt CR, Dillhoff M, Maithel SK, Pawlik TM (2018) J Surg Oncol 117: 868-878 Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C (2018) J Surg Oncol 117: 284-289 Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. Martin RC, Kooby DA, Weber SM, Merchant NB, Parikh AA, Cho CS, Ahmad SA, Kim HJ, Hawkins W, Scoggins CR (2011) J Gastrointest Surg 15: 175-83 Chemoembolization of hepatic malignancy. Gonsalves CF, Brown DB (2009) Abdom Imaging 34: 557-65 Case report: lanreotide in the management of hypercalcemia of malignancy. Anthony LB, May ME, Oates JA (1995) Am J Med Sci 309: 312-4
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.